Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Raleigh News & Observer Examines Efforts to Increase Sales of Antiretroviral Drug Fuzeon in North America

November 2, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The Raleigh News & Observer on Tuesday examined efforts by the Durham, N.C.-based pharmaceutical company Trimeris and Swiss pharmaceutical company Roche to increase sales of their antiretroviral drug Fuzeon in the North American market (Vollmer, Raleigh News & Observer, 11/1). Fuzeon, which is a fusion inhibitor, is administered with a needle and approved to treat HIV infection in combination with other antiretrovirals. Trimeris said that sales of Fuzeon dropped from $53.9 million in the second quarter of 2005 to $48.9 million in the third quarter. Although Fuzeon has not met the companies' expectations for sales since it launched the drug in 2003, sales had increased the previous three quarters (Kaiser Daily HIV/AIDS Report, 10/20). Currently, about 10% of eligible U.S. HIV-positive patients take Fuzeon. However, recent changes to treatment guidelines suggest using the drug in new combinations, which triples the number of U.S. patients who are eligible to receive the drug. According to Sharon Seiler, a Punk, Zielgel analyst in New York, the number of prescriptions for Fuzeon rose significantly between August and September (Raleigh News & Observer, 11/1). In addition, Roche and Trimeris in July announced they have filed for FDA approval to use Bioject Medical Technologies' Biojector 2000 injection system, a needle-free injection device, to administer Fuzeon (Kaiser Daily HIV/AIDS Report, 10/20). FDA is expected to decide on the application by mid-November (Raleigh News & Observer, 11/1).

Back to other news for November 2, 2005


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2005 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on T-20 (Enfuvirtide, Fuzeon)

Tools
 

Advertisement